Literature DB >> 22452453

Physiologically-based pharmacokinetic (PBPK) models for assessing the kinetics of xenobiotics during pregnancy: achievements and shortcomings.

G Lu1, K Abduljalil, M Jamei, T N Johnson, H Soltani, A Rostami-Hodjegan.   

Abstract

The physiological changes that occur in the maternal body and the placental-foetal unit during pregnancy influence the absorption, distribution, metabolism, and excretion (ADME) of xenobiotics. These include drugs that are prescribed for therapeutic reasons or chemicals to which women are exposed unintentionally from the surrounding environment. The pregnancy physiologically-based pharmacokinetic (p-PBPK) models developed for theoretical assessment of the kinetics of xenobiotics during pregnancy should take into account all the dynamic changes of the maternal and embryonic/foetal physiological functions. A number of p-PBPK models have been reported for pregnant animals and humans in the past 3 decades which have mainly been applied in the risk assessment of various environmental chemicals. The purpose of this review is to critically evaluate the current state of the art in p-PBPK modelling and to recommend potential steps that could be taken to improve model development and its application particularly in drug discovery and development for pregnant women, with potential implications for optimal drug treatment in pregnancy. The pregnancy-induced changes in physiology and pharmacokinetics, including metabolism, are reviewed to illustrate the basic alterations essential for pregnancy model development. A systemic search of the literature for existing p-PBPK models is carried out and the model structures, governing equations, methods of modelling growth, model validation/verification as well as model applications are highlighted. This review discusses benefits and limitations of the reported p-PBPK models so far and suggests areas for model improvement. The need for establishing databases on the system-related (biological, anatomical and physiological) and drug-related (physiochemical, affinity to enzymes and transpoorters) parameters for healthy and unhealthy pregnancies is particularly emphasized.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22452453     DOI: 10.2174/138920012800840374

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  14 in total

1.  A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4.

Authors:  Lu Gaohua; Khaled Abduljalil; Masoud Jamei; Trevor N Johnson; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

Review 2.  Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.

Authors:  Jennifer E Sager; Jingjing Yu; Isabelle Ragueneau-Majlessi; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2015-08-21       Impact factor: 3.922

3.  Fetal Physiologically-Based Pharmacokinetic Models: Systems Information on Fetal Biometry and Gross Composition.

Authors:  Khaled Abduljalil; Trevor N Johnson; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

4.  Population pharmacokinetics of 17α-hydroxyprogesterone caproate in singleton gestation.

Authors:  Shringi Sharma; Steve Caritis; Gary Hankins; Menachem Miodovnik; Mary F Hebert; Don Mattison; Raman Venkataramanan
Journal:  Br J Clin Pharmacol       Date:  2016-07-13       Impact factor: 4.335

Review 5.  Update in fetal anesthesia for the ex utero intrapartum treatment (EXIT) procedure.

Authors:  Pornswan Ngamprasertwong; Alexander A Vinks; Anne Boat
Journal:  Int Anesthesiol Clin       Date:  2012

6.  A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women.

Authors:  Alice Ban Ke; Srikanth C Nallani; Ping Zhao; Amin Rostami-Hodjegan; Nina Isoherranen; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2013-01-25       Impact factor: 3.922

7.  Differences in cytochrome p450 enzyme expression and activity in fetal and adult tissues.

Authors:  Joshua F Robinson; Emily G Hamilton; Juleen Lam; Hao Chen; Tracey J Woodruff
Journal:  Placenta       Date:  2020-08-06       Impact factor: 3.481

8.  Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling.

Authors:  Jolien J M Freriksen; Stein Schalkwijk; Angela P Colbers; Khaled Abduljalil; Frans G M Russel; David M Burger; Rick Greupink
Journal:  Clin Pharmacol Ther       Date:  2020-01-24       Impact factor: 6.875

9.  A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction.

Authors:  A B Ke; S C Nallani; P Zhao; A Rostami-Hodjegan; J D Unadkat
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-09-26

10.  The future of physiologically based pharmacokinetic modeling to predict drug exposure in pregnant women.

Authors:  A A Vinks
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.